- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02208089
Simultaneous TransPRK and Corneal Collagen Cross-Linking (TransPRKCXL)
A Prospective Trial of Simultaneous Combined Transepithelial Photorefractive Keratectomy and Corneal Collagen Cross-linking for Keratoconus
Young patients with keratoconus face two problems: disease progression and corneal shape irregularity leading to poor vision even in spectacles.
Corneal collagen cross-linking (CXL) is a new treatment designed to halt disease progression in keratoconus. The aim is to stiffen the cornea thereby preventing further shape deterioration.
Topography or wavefront guided transepithelial photorefractive keratectomy (transPRK) uses the excimer laser (the laser used to correct sight in 'laser eye surgery') to reduce corneal shape irregularity in early stage keratoconus, reducing dependence on contact lenses.
In transPRK, the corneal skin layer is removed in a well controlled, no touch procedure, preparing the cornea for CXL. Performing both treatments simultaneously (combining both procedures in one operation) may offer several advantages over performing CXL first then waiting for corneal shape to stabilise before performing transPRK. In particular, visual rehabilitation may be faster. This study aims to evaluate visual recovery after simultaneous CXL and transPRK in progressive early stage keratoconus. Visual recovery in these patients will be compared with results for a similar group of patients with early stage keratoconus who have already been treated with CXL alone.
Study Overview
Status
Conditions
Detailed Description
Features which distinguish this trial from previous trials of combined photorefractive keratectomy (PRK) and corneal collagen cross-linking (CXL) are: a rapid, pulsed light, CXL protocol; and a treatment programming algorithm for PRK designed to target higher order aberrations only with no compensatory additional laser corneal tissue removal.
Excimer laser treatment will be performed with the Schwind Amaris 750S laser (www.eye-tech-solutions.com). Unique features of this system utilised here include:
- Pre-programmed transepithelial ablation - laser removal of the minimum area of corneal epithelium required for PRK promoting more rapid recovery than conventional methods (20% alcohol application and manual epithelial removal). An 8mm diameter ablation zone will be applied throughout.
- Enhanced algorithms for minimal laser tissue removal - in this trial, the investigators are targeting higher order aberrations only (coma in particular) with the aim of improving spectacle corrected visual acuity without regard to the predicted spherocylindrical outcome. Unlike other current excimer laser platforms, Schwind Amaris treatment programming software allows treatment for irregular astigmatism without additional compensatory laser tissue removal to correct the spherocylindrical change induced by treatment of higher order aberrations. Higher order aberrations can also be treated selectively. The investigators will use an algorithm step that targets only aberrations (up to 6th order Zernike polynomials) with a value greater than 2 standard deviations from the population mean in normative data. These treatment planning steps allow the laser to create a large diameter treatment with minimal treatment depth.
Laser epithelial removal alone (transPTK at depth 55µm) removes a maximum 65µm of tissue in the corneal periphery. For patients with 390µm at the thinnest point, transPTK will therefore leave above 325µm residual stromal thickness prior to CXL. This is in line with recommendations for minimum stromal thickness after epithelial removal in the CXL protocol used here. Limited stromal reshaping is achieved in this simple embodiment of transPRK for keratoconus by taking advantage of the masking effect of the corneal epithelium, which tends to be thinnest over the cone apex. Where the thinnest point is greater than 390µm, further reductions in corneal shape irregularity can be produced by adding either wavefront or topography guided additional stromal ablation using custom programming on the Schwind Amaris laser. Ocular wavefront (aberrometry) guided smoothing will be used for patients with a 5.5mm or larger pupil at scanning and a consistent scan sequence (3 scans within 0.5 dioptre (D) spherical equivalent refraction). Corneal wavefront (topography) guided smoothing will be used for patients with ocular wavefront scans which do not meet these criteria. In all cases, a minimum corneal stromal thickness prior to CXL of 325µm will be preserved.
Immediately after PRK, corneal collagen cross-linking will be performed using the following protocol
Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.
UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)
Mitomycin C will not be used. A bandage contact lens will be applied at the end of treatment and a standard post photorefractive keratectomy topical and systemic drug treatment regimen will be used in every case with initial clinical review 1 week after surgery.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, EC1V 2PD
- Moorfields Eye Hospital NHS Foundation Trust, 162 City Road
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with progressive stage II or III keratoconus
- CDVA < 0.00 logMAR or subjective problems with spectacle corrected visual quality (ghost images or light scatter symptoms)
Exclusion Criteria:
- Active ocular surface disease
- Minimum corneal thickness <390µm (leaving 325µm residual stromal thickness after transPTK - in line with minimum thickness recommendations for the study CXL protocol)
- Vulnerable groups (patients whose capacity for giving informed consent to participate in the trial may be impaired)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TransPRKCXL
Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL)
|
Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only.
TransPRK will be followed immediately by corneal collagen cross-linking (CXL).
Other Names:
Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure. UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)
Other Names:
|
Active Comparator: CXL only
Corneal collagen cross-linking (CXL) using the same protocol without transepithelial photorefractive keratectomy
|
Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure. UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in LogMAR Corrected Distance Visual Acuity (CDVA)
Time Frame: Preoperative vs 24 months
|
Change in spectacle corrected logarithm minimum angle of resolution (LogMAR) distance visual acuity recorded in a 4m testing lane in photopic lighting conditions between baseline measurement and final review at 24 months (note that negative change = better vision; 0.1 logMAR units = 1 line on the test chart)
|
Preoperative vs 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinically Significant Visual Gain
Time Frame: Preoperative vs 24 months postoperative
|
Number of participants with gain of ≥2 lines (≥0.20 logMAR units) corrected distance visual acuity (CDVA) on a standard 5 letter per line EDTRS visual acuity testing chart
|
Preoperative vs 24 months postoperative
|
Clinically Significant Visual Loss
Time Frame: preoperative vs 24 months postoperative
|
Number of participants with loss of ≥2 lines (≥0.20 LogMAR units) corrected distance visual acuity (CDVA)
|
preoperative vs 24 months postoperative
|
Change in Kmax - Maximum Local Anterior Corneal Surface Curvature on Tomography Map
Time Frame: Preoperative vs 24 months postoperative
|
Pentacam (www.oculus.de)
measure: Maximum local curvature (Kmax).
Reduction in dioptric value = corneal flattening
|
Preoperative vs 24 months postoperative
|
Progression Rate
Time Frame: 6 months postoperative - 24 months postoperative
|
The number of participants with possible keratoconus disease progression after treatment defined by a ≥1.5D increase in Kmax, anterior and posterior K2 (maximum local corneal curvature, maximum anterior and posterior meridional corneal curvature) measured using a Pentacam HD corneal tomographer (www.oculus.de).
|
6 months postoperative - 24 months postoperative
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bruce D Allan, MD FRCOphth, Moorfields Eye Hospital NHS Foundation Trust
- Principal Investigator: Dan M Gore, FRCOphth, Moorfields Eye Hospital NHS Foundation Trust
Publications and helpful links
General Publications
- Gore DM, Shortt AJ, Allan BD. New clinical pathways for keratoconus. Eye (Lond). 2013 Mar;27(3):329-39. doi: 10.1038/eye.2012.257. Epub 2012 Dec 21.
- Kanellopoulos AJ, Asimellis G. Keratoconus management: long-term stability of topography-guided normalization combined with high-fluence CXL stabilization (the Athens Protocol). J Refract Surg. 2014 Feb;30(2):88-93. doi: 10.3928/1081597X-20140120-03.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALLB1018
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Keratoconus
-
The Cleveland ClinicUniversity of MarylandEnrolling by invitationKeratoconus | Keratoconus, Unstable | Keratoconus, StableUnited States
-
Eye Hospital Pristina KosovoActive, not recruitingKeratoconus | Keratoconus of Right Eye | Keratoconus, Unstable, Right EyeKosovo
-
Tianjin Eye HospitalRecruitingScansys, Pentacam, Keratoconus, Subclinical KeratoconusChina
-
Tianjin Eye HospitalActive, not recruitingScansys, Pentacam, Corvis ST, Keratoconus, Subclinical KeratoconusChina
-
Heba Allah Nashaat MohamedAssiut UniversityRecruitingKeratoconus, CollagenEgypt
-
Kent Wellish MDNot yet recruitingKeratoconus, Unstable
-
Kasr El Aini HospitalUnknownProgressive KeratoconusEgypt
-
Centre Hospitalier Régional Metz-ThionvilleCompletedProgressive Keratoconus
-
Glaukos CorporationCompletedProgressive KeratoconusUnited States
-
Tianjin Eye HospitalCompletedKeratoconus, StableChina
Clinical Trials on Transepithelial Photorefractive Keratectomy (TransPRK)
-
Bausch & Lomb IncorporatedCompletedAmetropiaPhilippines
-
Minia UniversityCompletedMyopia | Refractive SurgerySaudi Arabia, Egypt
-
Tabriz UniversityCompletedAstigmatismIran, Islamic Republic of
-
Assiut UniversityRecruitingCompare Corneal High Order Aberrations Before and After Stream Light Trans-PRK and Mechanical Photorefractive KeratectomyEgypt
-
Baylor College of MedicineActive, not recruitingHyperopia | High Myopia | Anisometropia | Amblyopia Isometropic | Amblyopia Bilateral | High AstigmatismUnited States
-
Walter Reed Army Medical CenterUnited States Naval Medical Center, San DiegoCompleted
-
Assiut UniversityCompletedMyopia ≤ -6 Diopters or Myopic Astigmatism ≤ -4 DioptersEgypt
-
Yonsei UniversityCompletedModerate KeratoconusKorea, Republic of
-
Assiut UniversityCompleted
-
University of UtahTerminatedTopo-guided LASIK and Photorefractive Keratectomy vs Wavefront LASIK and Photorefractive KeratectomySurgery | MyopiaUnited States